Welcome to our dedicated page for Adc Therapeutics Sa news (Ticker: ADCT), a resource for investors and traders seeking the latest updates and insights on Adc Therapeutics Sa stock.
ADC Therapeutics SA (NYSE: ADCT) is a commercial-stage oncology company focused on antibody drug conjugates, and its news flow centers on clinical progress, regulatory developments, and corporate updates. The company’s primary product, ZYNLONTA (loncastuximab tesirine-lpyl), is a CD19-directed ADC approved under accelerated and conditional pathways for certain adults with relapsed or refractory diffuse large B-cell lymphoma after at least two prior systemic therapies.
News about ADCT commonly includes updates from its LOTIS clinical program, such as the Phase 3 LOTIS-5 trial of ZYNLONTA plus rituximab in second-line or later DLBCL and the Phase 1b LOTIS-7 trial evaluating ZYNLONTA in combination with bispecific antibodies and other agents in B-cell non-Hodgkin lymphoma. Company releases have highlighted response rates, safety findings, and enrollment milestones from LOTIS-7, as well as anticipated timelines for sharing full data and pursuing regulatory and compendia strategies.
Investors and followers of ADCT news will also find announcements on preliminary revenue and cash estimates, participation in healthcare conferences, and equity-related actions such as employee inducement grants and private placements. These items appear in both press releases and related Form 8-K filings, giving context on the company’s commercial performance and financing plans alongside its clinical pipeline.
This news page aggregates such disclosures so readers can track ADCT’s key events, from clinical trial readouts and investigator-initiated study updates in indolent lymphomas to progress on its early-stage PSMA-targeting ADC. For those monitoring ADCT stock, revisiting this page provides a consolidated view of the company’s evolving clinical, regulatory, and corporate narrative.
ADC Therapeutics (NYSE:ADCT) announced the conclusion of enrollment in its pivotal Phase 2 clinical trial for camidanlumab tesirine (Cami) targeting relapsed or refractory Hodgkin lymphoma, with a total of 117 patients enrolled. Preliminary Phase 2 results showed an impressive 83% overall response rate in 47 evaluable patients, maintaining safety profiles from Phase 1. CMC aims to address unmet needs in heavily pre-treated patients and anticipates reporting updated interim data in the first half of the year.
ADC Therapeutics (NYSE:ADCT) has launched an expanded access program (EAP) for loncastuximab tesirine (Lonca), aimed at patients in the U.S. with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This program targets patients who lack treatment options. The FDA is reviewing Lonca's Biologics License Application with a target date of May 21, 2021, for its potential approval. Lonca, an investigational ADC targeting CD19, has shown a promising 48.3% overall response rate in a pivotal Phase 2 trial, exceeding key endpoints.
ADC Therapeutics SA (NYSE:ADCT) announced participation in the SternIR Virtual Corporate Access Event from January 11-14, 2021. The pre-recorded presentation will be available for on-demand viewing starting January 11 at 7:00 a.m. ET and can be accessed through their Investors section for 30 days. ADC Therapeutics focuses on developing antibody drug conjugates (ADCs) for oncology, with lead candidates showing promising clinical results in lymphoma treatments.
ADC Therapeutics (NYSE: ADCT) has entered a joint venture with Overland Pharmaceuticals, forming Overland ADCT BioPharma (CY) Limited. Under this agreement, ADC has licensed exclusive rights for the development and commercialization of four drugs, including Lonca, in Greater China and Singapore. Overland Pharmaceuticals will invest $50 million, acquiring a 51% stake, while ADC retains 49%. This strategic partnership aims to expand access to innovative therapies in oncology and could result in additional milestone payments and royalties for ADC.
ADC Therapeutics (NYSE:ADCT) and Overland Pharmaceuticals have established Overland ADCT BioPharma (CY) Limited to develop four ADC product candidates for hematologic and solid tumors in Greater China and Singapore. Overland Pharmaceuticals has invested $50 million, granting them a 51% stake. ADC Therapeutics retains 49% and can earn milestone payments and royalties. The lead product, Loncastuximab tesirine (Lonca), has shown a 48.3% overall response rate in pivotal trials for relapsed DLBCL. The partnership aims to expand access to innovative therapies in the licensed territories.
ADC Therapeutics (NYSE:ADCT) released updated clinical data for its lead programs, loncastuximab tesirine (Lonca) and camidanlumab tesirine (Cami), at the ASH Annual Meeting. Lonca's pivotal LOTIS 2 trial indicated a 48.3% overall response rate and a 24.8% complete response rate in patients with relapsed or refractory DLBCL. The FDA accepted Lonca's Biologics License Application for priority review, with a PDUFA date of May 21, 2021. Cami's Phase 2 trial showed an 83% overall response rate in Hodgkin lymphoma patients. Both drugs exhibit manageable safety profiles.
ADC Therapeutics SA (NYSE:ADCT) announced a live conference call on December 7, 2020, at 8:00 a.m. ET to showcase presentations at the 62nd ASH Annual Meeting. Key presentations will focus on the lead candidate, loncastuximab tesirine (Lonca), for treating relapsed diffuse large B-cell lymphoma and camidanlumab tesirine (Cami) for Hodgkin lymphoma. Lonca has a 48.3% overall response rate in a Phase 2 trial, while Cami showed an 86.5% response in Phase 1. The call will include insights from expert Mehdi Hamadani, MD, and will be available via webcast.
ADC Therapeutics SA (NYSE: ADCT) announced the FDA's acceptance of its Biologics License Application (BLA) for loncastuximab tesirine (Lonca), targeting relapsed or refractory diffuse large B-cell lymphoma (DLBCL), with a priority review status. A PDUFA target date is set for May 21, 2021. The BLA is based on the LOTIS 2 trial, reporting a 48.3% overall response rate among 145 patients. Common severe adverse events included neutropenia (25.5%) and thrombocytopenia (17.9%). Long-term efficacy and safety data are pending further studies.
ADC Therapeutics (ADCT) reported its third quarter 2020 financial results and business highlights. Key points include the submission of a Biologics License Application for its drug Lonca to the FDA for treating relapsed DLBCL, with a commercial launch planned for mid-2021. The company initiated Phase 3 and Phase 2 clinical trials for Lonca, showing promising preliminary data from ongoing trials. Cash and cash equivalents reached $494.4 million. However, the adjusted net loss widened to $41.3 million from $31.1 million year-over-year, mainly due to increased operational costs.
ADC Therapeutics SA (NYSE: ADCT) announced that CEO Chris Martin will present a company overview at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 9:20 am ET. A live webcast will be accessible, and an archived version will be available post-event. The company specializes in developing antibody drug conjugates (ADCs) for hematological malignancies and solid tumors, with lead products Loncastuximab tesirine and Camidanlumab tesirine showing promising results in pivotal trials. For more details, visit adctherapeutics.com.